Clinical trials: Patients With Non-small Cell Lung Cancer
Non Small Cell Lung Cancer
Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.
This study is to evaluate the preliminary efficacy and safety of Chidamide combined with Envafolimab in patients with PD-1 inhibitor resistant advanced NSCLC.
- Trial name
- NCT05068427
- Testing
- Chidamide, Envafolimab
- Where
- 12 sites in China
- Volunteers
- 34 people
- Sponsor
- Chipscreen Biosciences, Ltd.
NSCLC Stage IV, NSCLC, Stage IIIC
Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy
This Observational study will explore the utility of the Biodesix, Inc. "PIR" (primary immune response) test to predict outcomes in treatment-naïve advanced stage NSCLC with PD-L1 tumor proportion score (TPS) > 50% and ECOG…
- Trial name
- BEACON-LUNG (NCT04676386)
- Testing
- Primary Immune Response (PIR) test by Biodesix, Inc.
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Addario Lung Cancer Medical Institute
NSCLC, Renal Cell Carcinoma
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
This study is designed to see if we can lower the chance of side effects from radiation in patients with breast, kidney, small cell lung cancer, non-small cell lung cancer or melanoma that has spread to the brain and who are also…
- Conditions
- NSCLC, Renal Cell Carcinoma, Breast Carcinoma, Melanoma
- Trial name
- HYPOGRYPHE (NCT05703269)
- Testing
- single fraction stereotactic radiosurgery (SSRS), fractionated stereotactic radiosurgery (FSRS)
- Where
- 34 sites in United States
- Volunteers
- 58 people
- Sponsor
- Wake Forest University Health Sciences
EGFR Mutant Advanced Non-small Cell Lung Cancer
A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
This study is a Phase I/II open-label, multi-center study to evaluate the safety, tolerability, PK, and an anti-tumor activity of JIN-A02, a 4th generation EGFR-TKI agent for oral administration, in EGFR mutant-positive, advanced…
- Trial name
- NCT05394831
- Testing
- JIN-A02
- Where
- 10 sites in United States, South Korea and 1 more
- Volunteers
- 150 people
- Sponsor
- J Ints Bio
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Cachexia; Cancer, Cachexia
Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
The purpose of this trial is to learn whether participants who take rilogrotug gain weight, have a better appetite, and have a better quality of life than participants who do not take rilogrotug (placebo arm).
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Trial name
- REACH (NCT07888075)
- Testing
- Rilogrotug
- Volunteers
- 950 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Non Small Cell Lung Cancer
Trial of Docetaxel Versus Vinorelbine as 1st Line Treatment in Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)
This trial will compare the efficacy of docetaxel versus vinorelbine as first-line treatment in elderly patients with advanced NSCLC.
- Trial name
- NCT00441922
- Testing
- Docetaxel, Vinorelbine
- Where
- 10 sites in Greece
- Volunteers
- 166 people
- Sponsor
- Hellenic Oncology Research Group
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
There has been limited benefit with angiogenesis inhibitor drugs in molecularly unselected patients in non-small cell lung cancer (NSCLC).
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
- Trial name
- NCT02299141
- Testing
- Nintedanib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Carcinoma, Non-Small-Cell Lung
Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC
Lung cancer is the leading cause of cancer deaths worldwide. It is estimated that, in 2004, 173,700 new cases of lung cancer will be diagnosed in the United States alone and 164,440 deaths due to this disease will occur(13) .
- Trial name
- Coimbra (NCT00561054)
- Testing
- CETUXIMAB
- Where
- Portugal
- Volunteers
- 47 people
- Sponsor
- Grupo Portugues de Estudo do Cancro do Pulmao
Advanced Solid Tumors, Breast Cancer
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
This is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT07169994
- Testing
- YL202 for injection; Toripalimab injection, YL202 for injection; Furmonertinib Mesilate Tablets
- Where
- 20 sites in China
- Volunteers
- 414 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Lung Cancer
Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899756
- Testing
- molecular diagnostic method, mutation analysis
- Where
- Singapore
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lung Cancer (NSCLC)
Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer
In low-risk patients with stage I non-small cell lung cancer (NSCLC) surgical treatment with an anatomical resection is currently the standard of care.
- Trial name
- STRADOS (NCT07432802)
- Testing
- Stereotactic radiation therapy intervention, Surgical intervention
- Where
- 4 sites in Denmark
- Volunteers
- 182 people
- Sponsor
- Aarhus University Hospital
Breast Cancer, Non-small Lung Cancer
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
This is an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of oral GDC-0032 administered in combination with either docetaxel or with paclitaxel.
- Trial name
- NCT01862081
- Testing
- Docetaxel, GDC-0032, Paclitaxel
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 80 people
- Sponsor
- Genentech, Inc.
Non-small Cell Lung Cancer, Pancreatic Cancer
EGF Ointment for Erlotinib Skin Lesion
Epidermal growth factor receptor-tyrosin kinase inhibitor (EGFR-TKI, Erlotinib) has demonstrated its efficacy in patients with non-small cell lung cancer and pancreatic cancer.
- Trial name
- NCT01593995
- Testing
- Epidermal growth factor (EGF) ointment
- Where
- South Korea
- Volunteers
- 52 people
- Sponsor
- Dong-A University Hospital
Carcinoma, Non-Small-Cell Lung, Quality of Life
QOL After SURGERY and ADJUVANT Treatment
The goal of this prospective, observational study is to measure and analyze the effect of adjuvant treatment over the quality of life and recovery of patients undergoing pulmonary resection because of non-small cells lung cancer…
- Trial name
- NCT06115239
- Testing
- Questionnaires
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- University of Salamanca
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
This phase II MATCH treatment trial identifies the effects of trametinib and dabrafenib in patients whose cancer has genetic changes called BRAF V600 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439292
- Testing
- Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
This study will treat patients with advanced NSCLC harboring EGFR mutations. This is the first study to test DZD6008 combined with sunvozertinib in patients, which will help to understand what type of side effects with the…
- Trial name
- NCT07079475
- Testing
- DZD6008, Sunvozertinib, Osimertinib
- Where
- 14 sites in China
- Volunteers
- 220 people
- Sponsor
- Dizal Pharmaceuticals
Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma
Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung
This clinical trial investigates the acceptability of electronic cigarettes (JUUL) for smoking cessation (quitting smoking) and the reduction of surgery-related complications in patients with newly diagnosed head, neck, or lung…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Stage I Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage I Lung Cancer AJCC v8
- Trial name
- NCT05412875
- Testing
- Best Practice, Nicotine Replacement, Quality-of-Life Assessment
- Where
- United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
Non-small-cell Lung Cancer
Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions
Various driver gene mutations have been identified in lung cancer. Among them, human epidermal growth factor 2 (HER2) was identified in approximately 2% of non-small-cell lung cancers.
- Trial name
- NCT04382300
- Testing
- pyrotinib combined with thalidomide
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Chest Hospital
Locally Advanced Non-Small Cell Lung Cancer, Thoracic Radiotherapy
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with negative epidermal growth factor receptor (EGFR)-mutated unresectable locally advanced non-small cell lung cancer (LA-NSCLC).
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Thoracic Radiotherapy, Safety
- Trial name
- NCT07037680
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 44 people
- Sponsor
- JIANYANG WANG